Thursday, August 20, 2026. 12 PM-1:30 PM ET
Hear from an expert in HER2 IHC whose work has contributed to current scoring guidelines.
Webinar presenter Josef Ruschoff, MD, PhD, Former Chief Medical Officer and Co-Founder of Targos, Senior Consultant of Discovery Life Sciences, Kassel, Germany.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
To be rescheduled to a future date
Learn about digital pathology technology that is future-ready, yet practical for today’s
laboratory needs.
Webinar presenters Scott Hammond, Senior Systems Consultant, Digital Pathology Division, Wexner Medical Center, Department of Pathology, and Ursula Hofer, Imaging Technologist, Pathology Digital Imaging Lab, Wexner Medical Center, Department of Pathology, and Sandra Banky, PA(ASCP), Director of Operations, Wexner Medical Center, Department of Pathology.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
July 2026—Roche’s new Cobas Mass Spec solution will be on display this month at the ADLM meeting, as will Diasorin’s new Liaison Nes, Siemens Healthineers’ Atellica DT 250, and much more. CAP TODAY publisher Bob McGonnagle spoke online in late May with representatives of Roche, Diasorin, Sebia, and Siemens Healthineers about how their instruments will solve some of laboratories’ pressing problems. The conversation follows.
May 2026—Has your blood collection container been validated for the assays you have employed it for? At what point does a verification of a blood collection tube become a validation, and how is a laboratory supposed to know when this threshold has been crossed and what actions to take?
May 2026—Cystatin C has notable advantages over serum creatinine as a biomarker of kidney filtration: fewer nonglomerular filtration rate determinants, more accurate dosing of medications with narrow therapeutic windows for individuals with obesity or low muscle mass, and greater accuracy in determining eligibility for a kidney transplant or for a simultaneous liver-kidney or heart-kidney transplant.
March 2026—For a pathology that is invariably associated with dimming—of memory, of relationships, of personality—Alz-heimer’s disease has been linked to remarkably bright news as of late. Blood-based biomarkers, including two that garnered FDA approval last year, have cracked open the door to earlier diagnoses and therapeutic interventions, as well as the potential to reach more patients.
March 2026—Newer sepsis diagnostics, including monocyte distribution width, Intellisep, and MeMed BV, show promise in clinical studies but have limitations.
Two new ADLM documents provide guidance on toxicology testing for emergency departments, replacing a 2003 guideline. The documents address test menus, turnaround times, and the importance of educating ED staff on assay limitations.
November 2025—A 24-year-old female with hereditary stomatocytosis presented with a critical potassium concentration of 7.9 mmol/L. Despite ruling out common causes like hemolysis and EDTA contamination, the elevated potassium persisted, leading to a diagnosis of a PIEZ01 mutation causing potassium leakage.
October 2025—Speakers in a session at the ADLM meeting in July walked attendees through their real-life cases and quandaries that called for troubleshooting skill and left their laboratories with lessons learned from each. Offering up what they called lab adventures were Joe M. El-Khoury, PhD, DABCC, professor of laboratory medicine at Yale School of Medicine; Christopher Farnsworth, PhD, DABCC, associate professor of pathology and immunology at Washington University School of Medicine in St. Louis; and Reid Rosehill, MS, MLS(ASCP), laboratory manager at the University of California San Francisco.
June 2025—With few FDA-cleared or -approved methods for tumor marker testing in body fluids, it is the laboratory that’s responsible for the tests. “A specimen arrives at your door, and you have to figure out what, if anything, you’re going to do,” said Jonathan Genzen, MD, PhD, MBA.
June 2025—Patients who present to the ED with an elevated cardiac troponin above the 99th percentile and suspected acute coronary syndrome but in whom myocardial infarction is not diagnosed are at risk for future cardiac events. But how much risk? Last fall, the Food and Drug Administration cleared Siemens Healthineers’ Atellica IM High-Sensitivity Troponin I assay for prognostic risk stratification, an expanded intended use claim. Now, with this newly cleared use, “novel information is created from traditional indications,” said Christopher deFilippi, MD, who was recently director of the Biocore research laboratory and vice chair of academic affairs, Inova Schar Heart and Vascular in Fairfax, Va., and is now, since June 1, at the University of Maryland.
